| pubmed-article:2435052 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2435052 | lifeskim:mentions | umls-concept:C0042666 | lld:lifeskim |
| pubmed-article:2435052 | lifeskim:mentions | umls-concept:C0001418 | lld:lifeskim |
| pubmed-article:2435052 | lifeskim:mentions | umls-concept:C0345967 | lld:lifeskim |
| pubmed-article:2435052 | lifeskim:mentions | umls-concept:C2709248 | lld:lifeskim |
| pubmed-article:2435052 | lifeskim:mentions | umls-concept:C0003250 | lld:lifeskim |
| pubmed-article:2435052 | lifeskim:mentions | umls-concept:C0011906 | lld:lifeskim |
| pubmed-article:2435052 | lifeskim:mentions | umls-concept:C1369034 | lld:lifeskim |
| pubmed-article:2435052 | lifeskim:mentions | umls-concept:C0487602 | lld:lifeskim |
| pubmed-article:2435052 | lifeskim:mentions | umls-concept:C0521115 | lld:lifeskim |
| pubmed-article:2435052 | lifeskim:mentions | umls-concept:C0449435 | lld:lifeskim |
| pubmed-article:2435052 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:2435052 | pubmed:dateCreated | 1987-3-31 | lld:pubmed |
| pubmed-article:2435052 | pubmed:abstractText | The occurrence and coexpression of the cytoskeletal proteins vimentin and cytokeratins were studied in malignant mesotheliomas and pulmonary carcinomas. For this purpose a double immunoenzyme staining with monoclonal antibodies was developed which made it possible to visualize vimentin and cytokeratins simultaneously within the same cell. A clear distinction between stromal cells (vimentin only) and tumour cells was also obtained. A total of 12 mesotheliomas (six mixed type and six epithelioid type) and 13 carcinomas (eight adenocarcinomas and five large cell undifferentiated carcinomas) were studied. The results revealed a clear difference between mesotheliomas and adenocarcinomas: 11 of 12 mesotheliomas showed coexpression of vimentin and cytokeratins in at least 50% of the tumour cells, while in seven of the eight adenocarcinomas none or only a few cells could be seen with this coexpression. In the undifferentiated large cell carcinomas three of five expressed both components, but in less than 25% of the cells. It is concluded that a reliable double immunoenzyme staining of vimentin and cytokeratins can be used as an additional means to distinguish malignant mesothelioma from pulmonary adenocarcinoma. | lld:pubmed |
| pubmed-article:2435052 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2435052 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2435052 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:2435052 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2435052 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2435052 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2435052 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2435052 | pubmed:issn | 0340-6075 | lld:pubmed |
| pubmed-article:2435052 | pubmed:author | pubmed-author:MeijerC JCJ | lld:pubmed |
| pubmed-article:2435052 | pubmed:author | pubmed-author:MullinkHH | lld:pubmed |
| pubmed-article:2435052 | pubmed:author | pubmed-author:Henzen-Logman... | lld:pubmed |
| pubmed-article:2435052 | pubmed:author | pubmed-author:TademaT MTM | lld:pubmed |
| pubmed-article:2435052 | pubmed:author | pubmed-author:Alons-van... | lld:pubmed |
| pubmed-article:2435052 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2435052 | pubmed:volume | 52 | lld:pubmed |
| pubmed-article:2435052 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2435052 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2435052 | pubmed:pagination | 55-65 | lld:pubmed |
| pubmed-article:2435052 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:2435052 | pubmed:meshHeading | pubmed-meshheading:2435052-... | lld:pubmed |
| pubmed-article:2435052 | pubmed:meshHeading | pubmed-meshheading:2435052-... | lld:pubmed |
| pubmed-article:2435052 | pubmed:meshHeading | pubmed-meshheading:2435052-... | lld:pubmed |
| pubmed-article:2435052 | pubmed:meshHeading | pubmed-meshheading:2435052-... | lld:pubmed |
| pubmed-article:2435052 | pubmed:meshHeading | pubmed-meshheading:2435052-... | lld:pubmed |
| pubmed-article:2435052 | pubmed:meshHeading | pubmed-meshheading:2435052-... | lld:pubmed |
| pubmed-article:2435052 | pubmed:meshHeading | pubmed-meshheading:2435052-... | lld:pubmed |
| pubmed-article:2435052 | pubmed:meshHeading | pubmed-meshheading:2435052-... | lld:pubmed |
| pubmed-article:2435052 | pubmed:meshHeading | pubmed-meshheading:2435052-... | lld:pubmed |
| pubmed-article:2435052 | pubmed:meshHeading | pubmed-meshheading:2435052-... | lld:pubmed |
| pubmed-article:2435052 | pubmed:meshHeading | pubmed-meshheading:2435052-... | lld:pubmed |
| pubmed-article:2435052 | pubmed:meshHeading | pubmed-meshheading:2435052-... | lld:pubmed |
| pubmed-article:2435052 | pubmed:year | 1986 | lld:pubmed |
| pubmed-article:2435052 | pubmed:articleTitle | Simultaneous immunoenzyme staining of vimentin and cytokeratins with monoclonal antibodies as an aid in the differential diagnosis of malignant mesothelioma from pulmonary adenocarcinoma. | lld:pubmed |
| pubmed-article:2435052 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2435052 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2435052 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2435052 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2435052 | lld:pubmed |
